Loading publications…
The last 5 uploaded publications
Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304)
Ciara Conduit, Andrisha–Jade Inderjeeth, R.J. Allen, Andrew Martin, Wendy R. Parulekar, Eibhlin Mulroe, Margaret McJannett, Robert Zielinski, Alastair Thomson, Thean Hsiang Tan, Shahneen Sandhu, M. Neil Reaume, David Pook, Scott North, Gavin Marx, Anthony M. Joshua, Lisa G. Horvath, Ray McDermott, Simon Chowdhury, Kim N., Alison Y. Zhang, Martin R. Stockler, Ian D. Davis, Christopher J. Sweeney (2025). Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304). , DOI: https://doi.org/10.1080/14796694.2024.2440277.
Article62 days agoA plain language summary of the results from the MAGNITUDE study assessing how effective and how safe niraparib and abiraterone acetate with prednisone is in patients with metastatic castration-resistant prostate cancer
Kim N., Dana E. Rathkopf, Matthew R. Smith, Eleni Efstathiou, Gerhardt Attard, David Olmos, Ji Youl Lee, Eric J. Small, Andrea Juliana Gomes, Guilhem Roubaud, Marniza Saad, Bogdan Żurawski, V.S. Sakalo, Gary Mason, Peter Francis, George Wang, Daphne Wu, Brooke Diorio, Angela Lopez‐Gitlitz, Shahneen Sandhu (2025). A plain language summary of the results from the MAGNITUDE study assessing how effective and how safe niraparib and abiraterone acetate with prednisone is in patients with metastatic castration-resistant prostate cancer. , DOI: https://doi.org/10.1080/14796694.2025.2470106.
Article62 days ago8-year outcomes of enzalutamide (ENZA) versus a non-steroidal anti-androgen (NSAA) for metastatic, hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304).
Alison Yan Zhang, Ian D. Davis, Hayley Thomas, Ronan Andrew McLaughlin, Thean Hsiang Tan, David Pook, Gavin Marx, Robert Zielinski, Shahneen Sandhu, Alastair Thomson, M. Neil Reaume, Scott North, John McCaffrey, Ray McDermott, Nicola Jane Lawrence, Lisa G. Horvath, Simon Chowdhury, Kim N., Martin R. Stockler, Christopher Sweeney (2025). 8-year outcomes of enzalutamide (ENZA) versus a non-steroidal anti-androgen (NSAA) for metastatic, hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304).. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.5090.
Article62 days agoA phase 3 trial of the androgen receptor ligand-directed degrader, BMS-986365, versus investigator’s choice in patients with metastatic castration-resistant prostate cancer (CA071-1000 - rechARge).
Kim N., Rana R. McKay, Shahneen Sandhu, José Ángel Arranz Arija, Philippe Barthélémy, Boris Hadaschik, Nobuaki Matsubara, Neal D. Shore, Dingwei Ye, Teresa Cascella, Irina Irincheeva, Stephanie Kreiser, Antoine Thiery-Vuillemin, Dana E. Rathkopf (2025). A phase 3 trial of the androgen receptor ligand-directed degrader, BMS-986365, versus investigator’s choice in patients with metastatic castration-resistant prostate cancer (CA071-1000 - rechARge).. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.tps5119.
Article62 days agoFinal Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial
Johann S. de Bono, He Meng, Zhen Shi, Małgorzata Nowicka, Sergio Bracarda, Cora N. Sternberg, Kim N., David Olmos, Shahneen Sandhu, Christophe Massard, Nobuaki Matsubara, Geng Chen, Nives Selak Bienz, Daniel Canter, Matthew Wongchenko, Christopher J. Sweeney (2025). Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial. , DOI: https://doi.org/10.1016/j.eururo.2024.12.015.
Article62 days ago